Project Grant R01EY038655
- Federal Project Grant Award Summary Eye C Better Corp received a $315,825 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective September 1, 2025 through August 31, 2026. The award funds development of a novel, non-invasive intraocular pressure (IOP) measurement technology called Photonic IOP Biomonitoring (PIB) designed to address glaucoma management challenges. Glaucoma affects over 5 million Americans and costs the U.S. economy...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded Oregon Health & Science University a $1.73 million Project Grant under the Vision Research program (CFDA 93.867) beginning September 1, 2025, with completion targeted for April 30, 2030. The award funds development of innovative ophthalmic imaging technologies and objective biomarkers to assess photoreceptor function and integrity in patients with retinal degeneration. The research addresses a critical clinical need by...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $421,136 Project Grant to the University of Maryland, College Park, effective August 1, 2025, through July 31, 2027, under the Vision Research program (CFDA 93.867). This award supports research into advanced wavefront shaping techniques designed to enable high-resolution fundus imaging in patients with ocular opacities—conditions affecting the cornea and lens that currently prevent effective posterior segment eye...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded The Schepens Eye Research Institute, Inc. a Project Grant totaling $540,213 under the Vision Research program (CFDA 93.867) to investigate the fibrosis-immunity interface in corneal transplantation. Beginning August 1, 2025, and extending through July 31, 2030, this research program will deliver scientific findings aimed at improving corneal transplant survival rates by elucidating the mechanisms by which myofibroblasts...
- Federal Grant Award Summary The Schepens Eye Research Institute, Inc. received a $1.79 million Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective September 1, 2025 through August 31, 2027. The award funds research to develop and validate non-invasive transpalpebral electrical stimulation (TPES) as a therapeutic treatment for diabetic keratopathy, a corneal nerve damage condition affecting individuals with diabetes. The research will...
- Federal Project Grant Award Summary Kineolabs, Inc. received a $300,001 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) to develop a portable, low-cost line-scan swept-source optical coherence tomography imaging system (LS-SS-OCT). The system is designed for early detection and monitoring of age-related macular degeneration (AMD), diabetic retinopathy, and other eye diseases. The one-year project, which commenced July 1, 2025 and concludes June...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $527,987 Project Grant to the University of California, Los Angeles (UCLA) for the period May 1, 2026 through April 30, 2030 under the Vision Research program (CFDA 93.867). The award supports the development of an engineered, tunable biomimetic adhesive hydrogel platform designed to deliver mesenchymal stem cells (MSCs) to the cornea for regeneration and repair. The research addresses a critical bottleneck in corneal disease...
- Federal Grant Award Summary Award Details: Intelon Optics, Inc. received $566,288 in project grant funding from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded September 15, 2025, with an anticipated completion date of August 31, 2027. The performance location is Massachusetts. Products and Services: This project will develop a next-generation Brillouin Optical Scanner System (BOSS) that significantly improves upon the commercial BOSS Gen II device...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $571,206 Project Grant to the University of Maryland, Baltimore effective May 1, 2026, through March 31, 2030, under the Vision Research program (CFDA 93.867). This award funds the development, refinement, and validation of adaptive optics-optical coherence tomography (AO-OCT) biomarkers for glaucoma detection and progression monitoring. The project will deliver research products including validated imaging biomarkers capable...
- Federal Grant Award Summary Tufts University School of Medicine received a $144,618 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective September 1, 2025, through March 31, 2028. The award funds research investigating fucosylation as a mediator of limbal stem cell (LSC) viability to develop novel therapeutic approaches for limbal stem cell deficiency (LSCD), a potentially blinding condition with limited treatment options. The research...
The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded Massachusetts General Hospital a $643,357 Project Grant on June 15, 2026, to develop and validate a Brillouin microscopy-based imaging technology for direct measurement of corneal hydration. The primary deliverables include a combined Brillouin-optical coherence tomography (OCT) system capable of integrated functional and structural analysis of the cornea, along with high-resolution hydration mapping capabilities that are independent of corneal morphology. This technology addresses a significant clinical gap, as corneal hydration currently cannot be directly assessed in routine practice and is instead inferred from corneal thickness measurements, which are inherently variable and unreliable across patient populations. The research initiative, scheduled for completion by March 31, 2030, encompasses two specific aims: development of the integrated Brillouin-OCT imaging system and clinical application of the system to measure hydration patterns in human subjects with various corneal pathologies, including Fuchs' dystrophy, glaucoma, dry eye disease, keratoconus, and post-LASIK corneas. Upon successful completion, the technology is expected to provide transformative clinical capabilities for disease diagnosis, surgical planning, postoperative monitoring, and routine ophthalmic screening. The project will be conducted at the Massachusetts General Hospital Research Management Division in Cambridge, Massachusetts.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $643.4k | 6/16/26 |